

Safety Concerns for the HPV vaccine: Gardasil

- Gardasil was licensed in 2006 and up to September 2012 there were 21,265 adverse events (AE's) reported to the US CDC and FDA alone ¹⁴. Globally there have been many more AE's associated with HPV vaccines. The US CDC data includes 78 deaths, 363 life-threatening events, 609 permanently disabled, 2,000 cases listed as serious or prolonged hospitalisation and 9,565 requiring an emergency room visit ¹⁴.
- This is only a proportion of the AE's because the US CDC monitoring system and Australia's TGA monitoring system are *passive* surveillance systems ²⁴. This means they rely on voluntary reporting of temporal events *only*. As vaccine ingredients can cause delayed adverse events the only type of system that would be able to establish causal relationships with adverse events is an *active* surveillance system: one that follows the health outcomes for every vaccinated individual for a minimum of 1 year.
- The CDC and the TGA admit that the surveillance systems cannot establish causal relationships between the vaccine and the adverse events. This allows the government to claim that the adverse events are a 'coincidence'. This is not a scientific evidence-based policy.
- It is known that passive reporting systems will only represent about one-tenth of the possible adverse events that actually occur ²⁰. Any delayed reactions will not be reported.
- Despite the voluntary reporting of adverse events Gardasil has been responsible for 61% of all serious AE's compared to all other vaccines in the US vaccination schedule (including 63.8% of all deaths and 81.2% of all cases of permanent disability) in females younger than 30 years of age ¹⁴.
- HPV vaccine contains genetically modified DNA ¹³

- Gardasil contains 225 micrograms of aluminium adjuvant (225 ug amorphous aluminium hydroxyphosphate sulphate). Many times more than most vaccines and this adjuvant is known to cause allergies/anaphylaxis and autoimmune reactions in humans ²⁰
- The trials did not use a true placebo to test the safety of the vaccine. The manufacturer funded clinical trials used the adjuvant, aluminium hydroxyphosphate sulphate (classified as a neuro-immunotoxic substance) as the placebo in the unvaccinated group and this substance does not allow the researchers to accurately compare the adverse health outcomes that might occur from the vaccine with a group that is completely unvaccinated..
- For example, in the pre-licensure clinical trial for Gardasil there were 245 serious reactions (indicative of an autoimmune disease) from the ‘vaccine’ group and 218 from the ‘aluminium hydroxyphosphate sulphate’ group. How would these figures compare to a group with no vaccine or aluminium adjuvant? This is a flaw in the experimental design of the trial ²².
- Other ingredients of the vaccine include: sodium borate (borax), polysorbate 80, L-histidine hydrochloride, 4 recombinant VLP’s: HPV types – 16, 18, 11 and 6, amino Acids, carbohydrates, mineral salts, vitamins ¹³
- There are an unusually high number of AE’s associated with HPV vaccines with nervous-system-related disorders ranking the highest in frequency ¹⁴. When the global reports of adverse events are pooled for Gardasil the data suggests that the risks of HPV vaccination have not been fully evaluated in the pre-licensure trials ¹⁴.
- Yet the US CDC and the Australian TGA are evaluating selective data (not the global safety data) and they are concluding that ‘HPV vaccines are safe and effective’.

- The many known side-effects from HPV vaccines include death and life-long neurodegenerative/autoimmune disorders. These are documented in the pre-licensure clinical trials and at www.sanevax.org
- Over the past 2 decades pharmaceutical companies have gained unprecedented control over the evaluation and registration of their own products ¹⁴. This fact is reflected in the poorly designed safety and efficacy trials for vaccines for which there is no accountability.
- This is particularly the case because many vaccines are licensed in the USA where vaccine manufacturers are legally free from ordinary tort liability ²³. Vaccines are a product that are described as ‘unavoidably unsafe’ and there is no onus on manufacturers to make them as safe as possible because they are free from liability ²³
- Parents must ask if they wish their children to be subjected to the risk from a vaccine that has not been proven to prevent cervical cancer when there is already a safe and effective PAP screening procedure that will still be required anyway ¹⁴.

Judy Wilyman

www.vaccinationdecisions.net

References:

1. International Agency for Research on Cancer (WHO), 1995, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, volume 64, Human Papillomaviruses
2. Pfister H (Ed.), 1990, Papillomaviruses and Human Cancer, CRC Press Inc, USA

3. Australian Government, Department of Health and Ageing, 2005, "Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities, NHMRC, National Screening Program.
4. Haverkos H, 2005, Multifactorial Etiology of Cervical Cancer: A Hypothesis, *Medscape General Medicine*, v 7 (4): 57
5. Australian Government, Department of Health and Ageing, Office of Health Protection, 2009.
6. Future II Study Group, 2007, Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions, *The New England Journal of Medicine*, 356, 19, 1915 – 27.
7. Dayton L, 2011, The Australian, Ian Frazer's HPV vaccine may prevent cervical cancer, 19th June
8. Walboomers J, Jacobs M, Manos M, Bosch X, Kummer J, Shah K, Snijders P, Peto J, Meijer C, Munoz N, 1999, Human papillomavirus is a necessary cause of Invasive Cervical Cancer Worldwide, *Journal of Pathology*, vol. 189 p.12-19
9. Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global Cancer Statistics 2002, CA: *A Cancer Journal for Clinicians*, 2005; 55; 74-108
10. Australian of the Year Awards 2012, Australian of the Year 2006, <http://www.australianoftheyear.org.au/pages/page58.asp> visited November 2011
11. Clifford et al, 2005, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis, *The Lancet*, Vol 366, Is. 9490,2005,Pages 991-998

12. Australian Government, NCIRS, Human papillomavirus (HPV) Fact Sheet,
<http://www.ncirs.edu.au/immunisation/fact-sheets/hpv-human-papillomavirus-fact-sheet.pdf>
updated March 2013
13. Merck Inc, Clinical Review of Biologics License Application for Human
Papillomavirus 6, 11, 16, 18, L1 Virus Like Particle Vaccine (*S. cerevisiae*) STN
125126 GARDASIL), 2006 (June 8), manufactured by Merck Inc.
14. Tomljenovic L, Shaw CA, 2012, Too fast or not too fast: the FDA's approval of
Merck's HPV vaccine gardasil, *Journal of Law, medicine and Ethics*, 40 (3):673-681
15. Moscicki et al 2010 in Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw C,
2013, HPV vaccines and cancer prevention, science versus activism, *Infectious
Agents and Cancer Journal*, 8:6
16. Herskovits B. 2007, Brand of the Year, *Pharmaceutical Executive*, 27 (2): 58-65
17. a) Brisson M, Van de Velde N, Boily MC, Economic evaluation of human
papillomavirus vaccination in developed countries, *Public Health Genomics*,
August(5-6) 2009, vol 12: p 343 -51
b) Choi YH, Chaoman R, Gay N, Jit M, Potential overestimation of HPV vaccine
impact due to unmasking of non-vaccine types: Quantification using a multi-type
mathematical model, *Vaccine*, 2012, vol 30: p 3383 – 8
18. CSL Limited, Research and Development, Recent Highlights, Gardasil
<http://www.csl.com.au/research-development/recent-highlights.htm> visited November
2011
19. Uniquist, Technology Investment and Licensing, Gardasil – Human papilloma Virus
Vaccine, [https://www.uniquist.com.au/portfolio/gardasil-human-papilloma-virus-
vaccine](https://www.uniquist.com.au/portfolio/gardasil-human-papilloma-virus-vaccine) visited November 2011

20. S.A.N.E Vax Inc. Safe, Affordable, Necessary and Effective Vaccines,
www.sanevax.org visited 28 April 2011
21. Shoenfeld Y and Agmon-Levin N, 2011, ASIA – Autoimmunity/inflammatory syndrome induced by adjuvants, *Journal of Autoimmunity*, 36 p. 4-8.
22. C Exley, 2011, Aluminium-based adjuvants should not be used as placebos in clinical trials, *Vaccine*, 29, no. 50: 9289
23. 1986 National Childhood Vaccine Injury Act in Habakus and Holland 2011, Vaccine Epidemic: how corporate greed, biased science and coercive government threaten our human rights, our health and our children, Center for Personal Rights Inc, Skyhorse Publishing, 306th St New York ch 1.
24. US Centers for Disease Control and Prevention (CDC), Vaccine Safety, Reports of Health concerns following HPV Vaccination,
www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html visited Dec 2011.